“The Global Pharmaceutical Wholesale & Distribution market is estimated to be worth $1.3bn in 2023” says new Visiongain report

03 October 2018
Pharma

Visiongain has launched a new pharma report: Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018: Branded Drugs, Generic Drugs, Leading Companies

Growth in the global pharmaceutical wholesale and distribution market has remained steady in recent years. Growth is being held back by government price reductions and generic substitution of expensive branded drugs. However, the global demand for prescription medication is increasing. The ageing population in the developed markets is resulting in increasing prevalence of age-related diseases, which require medical treatment. In the emerging markets, the rapidly expanding middle class and increasing spending on healthcare is creating a high demand for medication. The pharmaceutical wholesale and distribution market is poised for strong growth.

The lead analyst of the report commented "Currently, most emerging pharmaceutical wholesale markets are much more fragmented than their developed counterparts. For example, in the US, the top 3 companies account for more than 95% of the country’s total market. China has seen rapid consolidation in recent years; there, the top 2 companies currently account for more than 45% of the market. The Chinese market will see further rapid consolidation during the forecast period.

During the forecast period there will be significant consolidation in the emerging markets. This will lead to a greater number of national wholesalers, able to serve all regions with greater efficiency and lower costs."

Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Anda Inc., Cardinal Health, CR Pharmaceutical, CuraScript Special, Fortissa Limited, H.D. Smith, Mawdsley-Brooks & Co. Ltd., McKesson, MEDIPAL HOLDINGS, Morris & Dickson Co. LLC, North Carolina Mutual Wholesale Drug, Prodigy Health, Shanghai Pharmaceutical Holdings., SINOPHARM, Smith Drug Company, SUZUKEN, The PHOENIX Group, Walgreens Boots Alliance

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focussing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever